DTYMK (deoxythymidylate kinase) catalyzes the ATP-dependent phosphorylation of deoxythymidine monophosphate (dTMP) to deoxythymidine diphosphate (dTDP), a critical precursor in the pyrimidine nucleotide biosynthetic pathway essential for DNA synthesis 1. This enzyme functions in both de novo and salvage pathways of thymidylate metabolism, operating in multiple cellular compartments including the cytoplasm, nucleus, and mitochondria. In cancer biology, DTYMK has emerged as a significant oncogenic driver. DTYMK is abnormally upregulated across multiple cancer types and correlates with poor prognosis, advanced tumor stage, and worse overall survival in hepatocellular carcinoma, lung adenocarcinoma, and other malignancies 23. Mechanistically, DTYMK promotes cancer cell proliferation through multiple pathways: it regulates cell cycle progression 3, activates STAT3 signaling 4, and enhances PI3K/AKT pathway activation 1. DTYMK expression correlates with functional hallmarks of malignancy including DNA damage/repair, epithelial-mesenchymal transition, and immune infiltration of B cells, CD4+/CD8+ T cells, macrophages, and dendritic cells 2. Clinically, elevated DTYMK serves as a diagnostic and prognostic biomarker across cancer types. DTYMK inhibitors (YMU1, pamiparib combinations) show therapeutic promise in suppressing lung adenocarcinoma and uveal melanoma progression 45. A known disease association exists with childhood-onset neurodegeneration with progressive microcephaly, though mechanistic details are absent from provided abstracts.